NCT03697408View on ClinicalTrials.gov

Itacitinib + Everolimus in Hodgkin Lymphoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

May 20, 2024

Study Completion Date

June 30, 2027

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Itacitinib

A JAK 1 selective small molecule inhibitor

DRUG

Everolimus

A mammalian target of rapamycin (mTOR) inhibitor

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT03697408 - Itacitinib + Everolimus in Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter